The 78th Annual Scientific Meeting of the Japanese Circulation Society (JCS) was held in Tokyo, Japan, on March 21–23, 2014, with the theme of “Cardiology in the Information Era: From Bench to Community”. The Tokyo International Forum (Figures 1A, B) was the main venue, but the JP Tower and the Tokyo Chamber of Commerce and Industry were also used. These venues are located in central Tokyo near the Tokyo station (Figure 1C), which has been partially restored to its original condition when it was built 100 years ago. The JP Tower, which was reopened last year after renovations, was built on the site of the historic “old Tokyo Central Post Office”, preserving part of its original appearance. Together, these buildings offered enough space for the meeting to be held in Tokyo for the first time in a decade. Furthermore, because of proximity to the imperial palace, “jog & walk around the palace” sessions were conducted on Sunday morning.

In addition to the scientific meeting, a medical history exhibition titled “The Dawn of Modern Medicine in Japan: From Dutch Medicine to German Medical Science” was hosted at the JP Tower, in collaboration with the Museum of the University of Tokyo. Thus, the meeting provided participants with the opportunity to enjoy both the scientific meeting itself and the interesting coexistence of modern and historic Tokyo.

Ryozo Nagai, MD, PhD, President of Jichi Medical University was Congress Chairperson and introduced the main theme (Figure 2A). In daily medical practice, clinicians need to process a vast amount of medical information. In clinical research, numerous clinical trials, physician-led clinical research and epidemiological studies are conducted. Moreover, basic research is generating tremendous amounts of information in a short period of time because of technological advancements. Therefore, we should thoroughly examine how that information is produced and interpret it with care. Only by having enough knowledge to eliminate the risks, can this enormous information base contribute to improving human health outcomes.

In the current information era, the use of registries is symbolic of clinical research. Many registries exist for both local purposes and restricted diseases, and some that are currently in progress were presented in Symposium 11. Each registry has the potential for significant impact in clinical medicine; however, of the registries in Japan, the only national database that gathers patient numbers and causes of cardiovascular disease is The Japanese Registry of all Cardiac And Vascular Diseases (JROAD). The progress of this unique registry was presented at the meeting.

The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.

Received July 23, 2014; accepted July 24, 2014; released online August 8, 2014
Cardiovascular Division, Tokyo University Hospital, Tokyo, Japan
Mailing address: Masafumi Watanabe, MD, PhD, Cardiovascular Division, Tokyo University Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: masafumi-tky@umin.ac.jp
All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp
all agreed on the importance of regulation, there were differences of opinion on the form that regulation should take.

Conflict of interest (COI) is an essential but difficult concept for researchers to understand. The lecture titled “Thought on COI” at Congress Chairperson’s Special Session 7, explained that although the original concept of COI was developed as a fine tuning tool, during the past decade or two it has needed to deal with the inherent conflicts between business-academia collaborations and the public nature of medicine. An important principal of COI is to ensure transparency with everybody involved, including patients.

Throughout these sessions, it was apparent that there was a sincere eagerness to conduct good clinical studies that benefited patients. In the future, clinical studies could be improved by greater collaboration among clinical doctors, epidemiologists, and medical statisticians. Moreover, a monitoring system is necessary to ensure the quality of data. We can surmount the risks of excess information generation through sound medical, ethical, and methodological knowledge.

Attendees and Sessions

This meeting comprised 45 lectures and more than 100 organized sessions. In total, 3,649 abstracts were submitted, of which 2,331 were accepted, including 125 abstracts for the featured research session (acceptance rate, 63.9%). The total reviewed in the Congress Chairperson’s Special Session 3. Initially, the registry was launched as a nationwide annual survey on the management of cardiovascular disease, and was intended to assess the clinical activities of general hospitals with cardiovascular beds. Later, the JCS expanded and renamed JROAD. It now truly reflects the real world of cardiovascular medical care in Japan, and could help drive future medical care policy.

Unfortunately, some Japanese clinical research into cardiovascular disease has received criticism for scientific misconduct. Therefore, several sessions were dedicated to lectures and discussions regarding sloppiness, forging, falsification, and fabrication. In the Congress Chairperson’s Special Session 4, titled “How Can We Conduct Sensible Investigator-initiated Clinical Research (IICR)?” Dr Kohro summarized the data management problems of the Kyoto Heart Study and explained how to improve the rigor of the study data. In Plenary Session 4, “Medical Guidelines for the Management of Cardiovascular Diseases and EBM in Japan”, Dr Ueshima pointed out the weaknesses of the prospective randomized, open, blinded endpoint (PROBE) studies. He emphasized that hard or objective endpoints are necessary for such studies to prevent biased results. In addition, he recommended asking whether the result was consistent with previous studies. The main discussion of this session focused on whether IICR should be regulated by law or the Good Clinical Practice (GCP) guidelines. Although
The most popular session on arrhythmia was “The First-Line Therapy for Paroxysmal AF” (Controversy 2). However, there was no definite answer to the question of whether we should select antiarrhythmic drug therapy or pulmonary vein isolation using radiofrequency catheter ablation. The arguments for catheter ablation emphasized 2 core arguments: when conducted by a skillful doctor, catheter ablation is better than drug therapy and lacks the potential risks of antiarrhythmic drug. Conversely, the drug therapy argument focused on the complications of catheter ablation therapy. The session on Controversy 4 concerning whether OAC therapy should be applied to patients with AF at relatively low risk for stroke was equally popular. Most presenters favored OAC therapy in such patients, but stressed the need to consider many factors, including economic ones, before making a decision.

Considering the emergence of new OACs (NOACs), the usage of OACs was another topic of great interest. In Symposium 10, “Prevention and Treatment of Atrial Fibrillation for the Prevention of Cerebral Infarction-Update”, Dr Inoue summarized the results of the J-RHYTHM Registry, which described AF management in the warfarin era. Although Western guidelines have been validated for Japanese patients with non-valvular AF, it may be necessary to lower the target INR levels.1 In the same session, Dr Akao reported the 1-year follow-up results of the prospective community-based Fushimi AF registry, which suggested that under-use and under-dosing with OACs are major problems.2 In Oral Presentation 15, the sub-

Arrhythmia

Atrial fibrillation (AF) was a major topic of this meeting, as a result of the new JCS guidelines for the pharmacotherapy of AF and the recent emergence of several nonvitamin K antag-

Figure 2. (A) Ryozo Nagai, MD, PhD, President of Jichi Medical University, presenting the Congress Chairperson’s Lecture. (B) Tadatsugu Taniguchi with the session’s chairperson, Shigetake Sasayama, at the Mashimo Memorial Lecture. (C) Eric N. Olson with the session’s chairperson, Yoshio Yazaki, at the Mikamo Lecture.
analysis of these registries suggested that sex does not relate to the risk for thromboembolic events among Japanese non-valvular AF patients, despite female sex being a risk factor in Western guidelines.

Although several NOACs have demonstrated similar or better efficacy and safety when compared with warfarin in global clinical trials, concerns remain. For example, the following questions were discussed: Can we directly extrapolate the results of these trials to patients with nonvalvular AF in Japan? Are there any beneficial biomarkers for monitoring NOACs? How should we perform antithrombotic therapy in AF patients undergoing coronary intervention? Are there ethnic differences in hemorrhagic stroke and bleeding between warfarin and NOACs?

In addition, genetic factors were shown to contribute to AF treatment. A recent meta-analysis of genome-wide association studies for AF has successfully identified 10 genotypes that are susceptible to AF. In Featured Research Session 7, Dr Fujii presented the newly developed genotype risk score that is based on these single nucleotide polymorphisms, and reported that the risk score was significantly associated with AF in patients with heart failure (HF).

**HF and Heart Implantation**

Diuretics, which are frequently used to treat HF patients, have limited evidence of effectiveness for HF. The vasopressin receptor antagonist, tolvaptan, became available more than 3 years ago, and clinical data have accumulated. The Round Table Discussion 5, “How to Use Diuretics in Patients with Acute Decompensated Heart Failure”, was the most popular session on HF. In this session, tolvaptan was reported to be effective for volume control in patients with endstage renal failure undergoing peritoneal dialysis. Moreover, tolvaptan had similar effects and less adverse events when compared with carperitide for acute decompensated HF. Urine osmolality (U-OSM) was proposed as a response determinant for tolvaptan because the baseline U-OSM and relative decreases in U-OSM after tolvaptan administration had a positive correlation with increased urine volume. In Late-Breaking Cohort Studies 2, Dr Kinugawa reported on the safety and efficacy of tolvaptan in HF patients from an interim post-marketing surveillance conducted as a prospective, multicenter, observational study. Given that this drug is expensive and has a unique functional mechanism, care should be taken when deciding who may benefit from this drug, in terms of both immediate effect and long-term prognosis.

The management of cardiovascular disease is increasingly complex; therefore, the importance of collaboration was emphasized in Symposium 5. An example of cooperation is the Heart Team, which presents medical information and recommendations to patients and families to assist them in deciding on the treatment of choice. For patients with HF, whether heart transplantation is necessary and whether a left ventricular assist device (LVAD) should be implanted are very important decisions. A similar situation arises in other cardiovascular areas, such as cardiac endarterectomy or carotid artery stenting, and in the selection of percutaneous coronary intervention or coronary artery bypass grafting. Another principal area of collaboration in HF treatment would be between cardiologists and cardiac surgeons, and the symposium reported on the practical aspects of collaboration for ventricular assist device therapy in the pre-, peri-, and postoperative care settings.

Topic 5, “The Latest Heart Failure Management for the Oldest-old”, was also popular. As aging of the population advances, it is important to understand the characteristics of HF in the elderly. Previous illnesses and comorbidities are common and the treatment of elderly patients can be long. With the numbers of elderly persons living with only the spouse or alone increasing, community support is not necessarily adequate, and many encounter difficulties with hospital visits and rehabilitation. Based on these factors, we must provide appropriate treatment and establish adequate daily support.

In younger patients, heart transplantation is available. In
Meet the Expert 7, the present state and future of heart transplantation in Japan were reported. Since the Organ Transplantation Law was established in 1997, there have been 185 heart transplantsations in Japan. The mean assist duration was reported to be approximately 2.3 years and the mean waiting duration for Status 1 patients was approximately 2.4 years. The primary disease among recipients was dilated cardiomyopathy. The 10-year survival rate is approximately 90%, which is superior to that of the International Society for Heart and Lung Transplantation registry. Despite the severe shortage of donors and the long waiting times on LVAD, the outcomes from heart transplantation in Japan are excellent.

**Ischemic Heart Disease (IHD)**

The number of popular sessions related to IHD was less than expected in this meeting. Special Lecture 3, titled “Update on the Pathophysiology of Acute Myocardial Infarction”, was the most popular session on this topic. Peter Libby talked about the role of inflammation in the pathophysiology of acute myocardial infarction (AMI) and acute coronary syndromes, and described the roles of interleukin-1β, the matrix metalloproteinase family, tissue factor, and the CD40 ligand. In addition, he argued that hemodynamic conditions of low shear stress may alter the interstitial collagenases. Finally, he mentioned 2 ongoing trials to test whether antiinflammatory therapy could reduce cardiovascular events. The first is the Cardiovascular Inflammation Reduction Trial (CIRT), which uses low-dose methotrexate and the other is the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial, which uses the human monoclonal antibody, canakinumab to selectively neutralizes IL-1β. If either is effective, it will support the inflammatory hypothesis and provide a novel cytokine-based therapy.

In clinical practice, although fractional flow reserve (FFR) is widely used to estimate whether an intermediate coronary stenosis produces significant myocardial ischemia, there are several unsolved problems. A new technique and strategy for FFR and relative coronary flow reserve were presented in Symposium 1. Over the past decade, stent thrombosis following drug-eluting stent (DES) implantation has been a major topic. In the late-breaking cohort studies session 1, late catch-up phenomenon of first generation sirolimus-eluting stents relative to bare-metal stents regarding stent thrombosis and target-lesion revascularization was reported from the data of the CREDO-Kyoto registry Cohort-2. In contrast, second-generation DES have been recently shown to have very low incidence of stent thrombosis. Their impact, and the role of novel antiplatelet agents, were reviewed and discussed in Round Table Discussion 3. There is increasing concern that aggressive antiatherothrombotic therapy can increase the risk of stroke in patients with coronary artery disease (CAD), particularly those with elevated systolic blood pressure. In another late-breaking cohort study of patients with CAD registered in the Japanese Coronary Artery Disease study (JCAD) study, antithrombotic therapy was found to have negligible effect on either ischemic or hemorrhagic stroke, if the systolic blood pressure was ≤140 mmHg.

**Control of Coronary Risk Factors**

The number of patients with diabetes mellitus (DM) is increasing, and many unanswered questions were discussed in Plenary Session 6. Glucose fluctuation and insulin resistance were proposed as the primary target for DM treatment in AMI. Glucose fluctuation, including the daily glucose profile, was also reported to affect coronary plaque vulnerability in patients with CAD who are pretreated with lipid-lowering therapy. In addition, cardiologists expect DM drugs to lower the incidence of cardiovascular events. Although some trials suggested pioglitazone may be promising, this theory was supported in a Japanese randomized trial (The J-DESSERT study), which analyzed patients with DM and CAD after DES implantation. We are expecting new DM drugs to have similar effects. Late-breaking clinical trials reported the new dyslipidemia medication, AMG-145, which is a monoclonal antibody to PCSK9. The Phase II randomized, double-blind, placebo-controlled YUKAWA Study reported that AMG-145 significantly reduced low-density lipoprotein cholesterol compared with placebo and was tolerated in high-risk Japanese patients.

After a series of angiotensin-receptor blockers, no new classes of antihypertensive drugs are due to be released. Therefore, the main topic of Symposium 7, “EBM in Hypertension”, focused on the optimal target ranges for blood pressure according to disease, such as type 2 DM, post-AMI, and HF. Topic 11 discussed the unresolved question of renal denervation (RD), which is expected to lower blood pressure. To reduce sympathetic nerve activity, catheter-based renal nerve ablation was performed in a patient with resistant hypertension in 2009. Furthermore, after this demonstrated clinically relevant blood pressure reduction, subsequent trials have provided further evidence of its safety and effectiveness. In addition, preliminary data obtained from small and uncontrolled studies indicate additional benefits for hypertensive end-organ damage, congestive HF, cardiac arrhythmias, chronic renal failure, insulin resistance, and sleep apnea. However, because those studies did not include a sham-control arm, the Symplicity HTN-3 study was designed to assess a lack of efficacy of RD against controls undergoing a sham procedure. The primary endpoint was any change in systolic blood pressure after 6 months. Unfortunately, just 2 months before this meeting, and despite a lack of safety concerns, this phase 3 study was suspended, having failed to achieve its primary endpoint. Given that RD is available in Europe, the presenter remains hopeful that it may be proven effective. Specifically, it was discussed why this study failed, the purported mechanism of lowering blood pressure, how to assess whether the procedure is sufficient to ablate the nerve, and which patients are most likely to respond to RD.

**Valve Disease and Other Diseases**

More than 700 people attended the Controversy 5 sessions, titled “The Interventional Treatment of Valvular Heart Disease in the Elderly”. To date, no effective drug therapy exists to treat or prevent the progression of aortic stenosis (AS). Though aortic valve replacement is the standard treatment, transcatheter aortic valve implantation (TAVI) has recently become available. Although TAVI has only just been introduced in Japan, it is increasingly popular in Europe because of its relatively less invasive nature. In late-breaking clinical trials 2, Dr Sawa reported on the first clinical trial of a self-expandable transcatheter heart valve in Japanese patients with symptomatic severe AS. In addition, TAVI was the main theme of topic 3, “Forefront of Hybrid Therapy in Cardiac and Vascular Therapy”, and Meet the ESC, “TAVI update”. Furthermore, transcatheter therapy could be aimed at mitral regurgitation (MR). Although early repair surgery for patients with degenerative MR is advocated, percutaneous transcatheter mitral valve repair may be used in the near future as an alternative for elderly patients with MR and high surgical risk.
Another important area in cardiovascular research is genomic analysis. Since the genome sequence project was completed, a tremendous amount of information has accumulated about the mutations and genome disorders associated with cardiovascular disease. In Special Session 6, “Advances in Genomic Medicine,” the cost of genome analysis was presented; in 2001, it took several months and cost $10 billion to complete the whole genome sequence, whereas it now takes several hours and costs several hundred thousand Japanese yen. Therefore, large amounts of data can be generated easily, but human resources, super-computers, money, and energy are required to analyze them. Western countries appear to be preparing resources and connecting data with electronic medical records to embrace a “tailored medical era”. However, this is not yet the case in Japan, and the strategy required to apply these genomic analysis to clinical medicine was summarized by Dr Seidman in her keynote lecture in Symposium 22. Discovering the genetic basis of disease may enable us to identify patients prior to overt disease, thereby providing opportunities for intervention that may delay the disease onset or attenuate its severity.

### Closing Remarks

The 78th Annual Scientific Meeting of JCS successfully offered future perspectives in cardiology. This report was based on abstracts and videos of the meeting.

### Acknowledgments

I thank Yasunobu Hirata for his useful suggestion and Dobun Hayashi for providing the photograph shown as Figure 1C.

### Disclosures

Conflict of Interest Statement: Received grants from Sumitomo Dainippon Pharma, Daiichi-Sankyo Company, Othuka Pharmaceutical, Phizer and Takeda Pharmaceutical Company for medical research over the past year.

### References